SOUTH PLAINFIELD, NJ, February 4, 2021 / PRNewswire / – PTC Therapeutics, Inc. (NASDAQ: PTCT) to host a conference call today at 5:30 p.m. ET to review the results of its clinical study 045 of Translarna ™ (ataluren) in patients with Duchenne muscular dystrophy with nonsense mutation.
The webinar can be accessed by dialing (877) 303-9216 (national) or (973) 935-8152 (international) five minutes before the start of the webinar and providing the access code 3495760. A live and streamed webcast Listen-only can be accessed on the Events & Presentations page in the Investor Relations section of the PTC Therapeutics website at www.ptcbio.com. The accompanying slide presentation will be posted in the Investor Relations section of the PTC website. A replay of the webinar will be available approximately two hours after the end of the webinar and will be archived for 30 days after the webinar.
About Duchenne muscular dystrophy
Primarily affecting men, Duchenne muscular dystrophy (Duchenne) is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. . It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is essential for the structural stability of all muscles, including skeletal, diaphragmatic and heart muscles. Patients with Duchenne may lose the ability to walk (loss of walking) as early as ten years of age, followed by loss of use of their arms. Duchenne’s patients subsequently develop life-threatening pulmonary complications, requiring ventilatory assistance, and cardiac complications in their late teens and twenties.
Further information on Duchenne is available from the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy. In addition, information and resources are available at www.duchenneandyou.com.
About Translarna ™ (ataluren)
Translarna (ataluren), discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functional protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely stops the synthesis of an essential protein. The resulting disorder is determined by the protein that cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna, the trade name for ataluren, is authorized in the European Economic Area for the treatment of Duchenne muscular dystrophy by nonsense mutation in ambulatory patients aged two years and older. Ataluren is an investigational new drug in the United States.
About PTC Therapeutics, Inc.
PTC is a global science-based biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated drugs that provide benefits to patients with rare diseases. PTC’s ability to market products globally is the foundation that drives investment in a strong and diverse pipeline of transformative medicines and our mission to provide access to the best treatments for patients with unmet medical need. .
For more information:
Media and investors:
+1 (908) 912-9167
Show original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-call-to-review-results-from-its-study-of-translarna-ataluren-in-patients-with-nonsense- mutation-duchenne-muscular-dystrophy-301222659.html
SOURCE PTC Therapeutics, Inc.